Ignite Creation Date:
2025-12-24 @ 11:52 PM
Ignite Modification Date:
2026-02-10 @ 11:45 AM
Study NCT ID:
NCT02657551
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-11
First Post:
2015-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study Using Regorafenib as Second or Third Line Therapy in Metastatic Medullary Thyroid Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization: